Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study

James Chih-Hsin Yang,Karen L. Reckamp,Young-Chul Kim,Silvia Novello,Egbert F. Smit,Jong-Seok Lee,Wu-Chou Su,Wallace L. Akerley,Collin M. Blakely,Harry J.M. Groen,Lyudmila Bazhenova,Enric Carcereny Costa,Rita Chiari,Te-Chun Hsia,Tony Golsorkhi,Darrin Despain,Danny Shih,Sanjay Popat,Heather Wakelee

JTO Clinical and Research Reports（2021）

引用 10|浏览11

暂无评分

摘要

Rociletinib had a more favorable median PFS versus chemotherapy but had higher rates of hyperglycemia and corrected QT prolongation in patients with advanced -mutated NSCLC who progressed on previous EGFR TKI. Incomplete enrollment prevented evaluation of the primary efficacy end point.

查看译文

关键词

EGFR tyrosine kinase inhibitor,Epidermal growth factor receptor mutations,Non–small cell lung cancer,Phase III randomized clinical trial,Rociletinib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要